Bio-Rad’s CFX Opus Deepwell Real-Time PCR Detection System is designed to support researchers in developing nucleic acid detection assays.
Bio-Rad Laboratories’s new CFX Opus Deepwell Real-Time Polymerase Chain Reaction (PCR) Detection System is designed to support researchers in developing nucleic acid detection assays. The product, launched in June 2022, is the latest in Bio-Rad’s portfolio of CFX Opus Real-Time PCR instruments.
The CFX Opus Deepwell has a 96-well block and a reaction volume of up to 125 µl, the largest in the CFX Opus range, according to Bio-Rad in a June 27, 2022 press release. The system can multiplex up to five targets simultaneously and supports fluorescence resonance energy transfer applications.
According to the release, the deeper sample wells are designed for workflows requiring larger reaction volumes for pooling, certain sample prep procedures, and other specialized protocols, such as food and industrial testing or veterinary pathogen detection. The CFX Opus Deepwell can be linked to Bio-Rad’s BR.io platform, which provides remote setup, instrument monitoring, and cloud data management solutions.
"We are witnessing an increasing demand for improved real-time PCR systems that offer more efficient workflows and enhanced data management and analysis," said Steven Blakely, director, Gene Expression and Software Technology, Bio-Rad, in the press release. "We're pleased to expand our portfolio of CFX Opus Detection Systems with the Deepwell format to help researchers perform experiments more efficiently and to consistently deliver robust datasets."
Source: Bio-Rad
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
August 2nd 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.